ClinicalTrials.gg
CompletedNCT00686920Updated Aug 14, 2019Results posted

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

A Phase 3 interventional study of Rifaximin in Hepatic Encephalopathy, sponsored by Bausch Health Americas, Inc.. Completed at 35 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-14.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2007, registered May 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
322
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing rifaximin in Hepatic Encephalopathy — 3 open to participants now, 3 under way, none of them phase 3. Rifaximin · Hepatic Encephalopathy.

Enrollment
2nd of 18
322 · median 94
Started
2007
with 1 other
Phase 3
4 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
4 of 18
Bausch Health Americas, Inc.

Among the 18 studies testing rifaximin in Hepatic Encephalopathy, this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 3, and was the 5th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

3 of the 18 studies testing rifaximin in Hepatic Encephalopathy are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rifaximin

Rifaximin: first FDA approval 2004 (XIFAXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rifaximin in Hepatic Encephalopathy, or all of them as a file.
02

Study summary

This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.

Read the detailed description

Eligible participants had a history of HE, a Conn score of 0 to 2 at enrollment, and either had successfully participated in a previous HE study with rifaximin (that is, RFHE3001 [NCT00298038]), or were new participants enrolled with ≥1 verifiable episode of HE (equivalent to a Conn score of ≥2) associated with cirrhosis or portal hypertension within 12 months of screening.

Successful participation in a previous rifaximin study was defined as having received ≥80% and ≤120% of the expected tablets, having been reasonably compliant with study procedures, and having not been discontinued from the previous study due to study drug-related Adverse Events. Participants who experienced HE or associated symptoms during or after the RFHE3001 study were considered eligible for entry into this open-label study if the participant and Investigator did not perceive study medication as a possible cause of the HE episode or associated symptoms. Participants who did not participate in a previous HE study with rifaximin were eligible if this open-label study was the only rifaximin HE study available at an individual site.

03

Conditions studied

  • Hepatic Encephalopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must sign an Form
  • In remission from past HE
  • Appropriate measures
  • More than or equal to 18 years of age
  • Must be potential for benefit from treatment
  • Recent HE episodes
  • Capable and willing to comply with all study procedures
  • Participant has support network

Exclusion criteria

Exclusion Criteria:

  • Significant medical conditions or Investigator decision not to include the participant
  • Allergies to the study drug or similar drugs
  • Laboratory abnormalities
  • Recent participation in another clinical trial
  • Problems experienced in a previous HE trial
  • Pregnant or at risk of pregnancy
  • Recent alcohol consumption
  • Active or latent bacterial or viral Infections
  • Bowel issues
  • Recent Active Cancer
  • On a prohibited medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    Rifaximin

    Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.

    Drug: Rifaximin

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event

    A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to Month 36

Secondary outcomes

  1. Number Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants

    Hematology and blood chemistry with potentially significant values included: Hemoglobin \<9, \>18, or ≥3 (grams/deciliter \[g/dL\]) decrease from previous visit or ≥4 g/dL decrease from baseline; Hematocrit \<0.27%, \>0.54%, or ≥0.10% decrease from previous visit or ≥0.15% decrease from baseline; Platelets \<50 or \>400\*10\^9/(liter \[L\]); Prothrombin time 9 seconds above baseline or upper limit of normal range; International normalized ratio \>1.7; White blood cells \<2.0 or \>12.0\*10\^9/L; Lymphocytes \<13.5% or \>70%; Glucose, random, serum \<2.2 or \>16.5 millimole (mmol)/L; Potassium ≤3.0 or ≥5.5 mmol/L; Direct bilirubin increases 3-fold from baseline or \>85.5 micromole (umol)/L. Baseline value was defined as the last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to Month 36

  2. Number Of Participants With A Significant Mean Change From Baseline In Vital Signs

    Vital signs were measured and included sitting blood pressure, heart rate, oral temperature, and weight. These were collected at each scheduled study visit. Participants were placed supine for 5 minutes prior to each assessment of vital signs. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline up to Month 36

  3. Change From Baseline In Conn Score At Last Assessment

    The assessment for change in mental status during the study was measured by the Conn score (also known as the West Haven score). The following scale was used in the Conn scoring system: Grade 0=No personality or behavioral abnormality detected. Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span; or impairment of addition or subtraction. Grade 2=Lethargy; disorientation for time; obvious personality change; and inappropriate behavior. Grade 3=Somnolence to semi-stupor, responsive to stimuli; confused; gross disorientation; and bizarre behavior. Grade 4=Coma, unable to test mental state. Participants entered the study with a Conn score of 0 to 2. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug.

    Time frame: Baseline up to Month 36

07

Results

Posted Aug 14, 2019

Participant flow

A total of 152 (47%) participants with hepatic encephalopathy (HE) rolled over from the double-blind study RFHE3001 (NCT00298038); 70 rifaximin participants (designated to the "Continued Rifaximin" arm in Study RFHE3002) and 82 placebo participants (designated to the "New Rifaximin" arm along with the new 170 \[53%\] participants in Study RFHE3002).

Participant flow — Overall Study
MilestoneNew RifaximinContinuing Rifaximin
Started25270
Received at least 1 dose of study drug25270
Completed12034
Not completed13236
Withdrew: Death4514
Withdrew: Liver transplant238
Withdrew: Recurrent hepatic encephalopathy episode12
Withdrew: Withdrawal by subject235
Withdrew: Protocol violation21
Withdrew: Adverse event102
Withdrew: Personal reason01
Withdrew: Lost to follow-up153
Withdrew: Moved to another state10
Withdrew: Transferred to nursing home10
Withdrew: Noncompliance90
Withdrew: Principal investigator decision20

Outcome measures

SecondaryNumber Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants

Hematology and blood chemistry with potentially significant values included: Hemoglobin \<9, \>18, or ≥3 (grams/deciliter \[g/dL\]) decrease from previous visit or ≥4 g/dL decrease from baseline; Hematocrit \<0.27%, \>0.54%, or ≥0.10% decrease from previous visit or ≥0.15% decrease from baseline; Platelets \<50 or \>400\*10\^9/(liter \[L\]); Prothrombin time 9 seconds above baseline or upper limit of normal range; International normalized ratio \>1.7; White blood cells \<2.0 or \>12.0\*10\^9/L; Lymphocytes \<13.5% or \>70%; Glucose, random, serum \<2.2 or \>16.5 millimole (mmol)/L; Potassium ≤3.0 or ≥5.5 mmol/L; Direct bilirubin increases 3-fold from baseline or \>85.5 micromole (umol)/L. Baseline value was defined as the last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to Month 36
Reported as:
Count of participants · Participants
Number Of Participants With Postbaseline Potentially Clinically Significant Laboratory (Hematology and Blood Chemistry) Abnormal Results In ≥5% of Participants
ParticipantsNew RifaximinContinuing Rifaximin
Hemoglobin1512
Hematocrit124
Platelets186
Prothrombin Time167
International Normalized Ratio248
White Blood Cells152
Lymphocytes2410
Glucose, random, serum88
Potassium177
Direct Bilirubin145
PrimaryNumber Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event

A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to Month 36
Reported as:
Count of participants · Participants
Number Of Participants Reporting A Non-serious Adverse Event Or A Serious Adverse Event
ParticipantsNew RifaximinContinuing Rifaximin
Non-Serious Adverse Event7815
Serious Adverse Event15849
SecondaryNumber Of Participants With A Significant Mean Change From Baseline In Vital Signs

Vital signs were measured and included sitting blood pressure, heart rate, oral temperature, and weight. These were collected at each scheduled study visit. Participants were placed supine for 5 minutes prior to each assessment of vital signs. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline up to Month 36
Reported as:
Count of participants · Participants
Number Of Participants With A Significant Mean Change From Baseline In Vital Signs
ParticipantsNew RifaximinContinuing Rifaximin
Number Of Participants With A Significant Mean Change From Baseline In Vital Signs00
SecondaryChange From Baseline In Conn Score At Last Assessment

The assessment for change in mental status during the study was measured by the Conn score (also known as the West Haven score). The following scale was used in the Conn scoring system: Grade 0=No personality or behavioral abnormality detected. Grade 1=Trivial lack of awareness, euphoria, or anxiety; shortened attention span; or impairment of addition or subtraction. Grade 2=Lethargy; disorientation for time; obvious personality change; and inappropriate behavior. Grade 3=Somnolence to semi-stupor, responsive to stimuli; confused; gross disorientation; and bizarre behavior. Grade 4=Coma, unable to test mental state. Participants entered the study with a Conn score of 0 to 2. Baseline value was defined as last available value (including the applicable values from the participants who rolled over from Study RFHE3001) prior to the first dose of study drug.

Time frame:
Baseline up to Month 36
Reported as:
Mean · score on a scale
Change From Baseline In Conn Score At Last Assessment
score on a scaleNew RifaximinContinuing Rifaximin
Baseline0.4 ± 0.580.2 ± 0.40
Change from Baseline-0.1 ± 0.770.1 ± 0.41

Adverse events

Collected over Baseline up to Month 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
New Rifaximin—158/252 (62.7%)212/252 (84.1%)
Continuing Rifaximin—49/70 (70%)52/70 (74.3%)
Most frequent serious events
Showing 10 of 221
Most frequent serious events
EventNew RifaximinContinuing Rifaximin
Hepatic encephalopathyNervous system disorders79/25218/70
Renal failure acuteRenal and urinary disorders30/2525/70
Hepatic cirrhosisHepatobiliary disorders7/2527/70
Liver transplantSurgical and medical procedures22/2527/70
Hepatic failureHepatobiliary disorders23/2525/70
AnaemiaBlood and lymphatic system disorders19/2526/70
AscitesGastrointestinal disorders15/2522/70
CellulitisInfections and infestations12/2524/70
Lobar pneumoniaInfections and infestations3/2524/70
Urinary tract infectionInfections and infestations8/2524/70
Most frequent other events
Showing 10 of 48
Most frequent other events
EventNew RifaximinContinuing Rifaximin
NauseaGastrointestinal disorders52/25215/70
Urinary tract infectionInfections and infestations50/25215/70
Oedema peripheralGeneral disorders48/25213/70
AscitesGastrointestinal disorders38/2526/70
HypokalaemiaMetabolism and nutrition disorders37/2528/70
VomitingGastrointestinal disorders34/2528/70
ConstipationGastrointestinal disorders33/2524/70
DiarrhoeaGastrointestinal disorders29/2529/70
DepressionPsychiatric disorders30/2529/70
FatigueGeneral disorders31/2527/70

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)New RifaximinContinuing RifaximinTotal
Mean57.6 ± 8.9056.7 ± 9.3657.4 ± 57.0
Sex: Female, Male
Sex: Female, Male(Participants)New RifaximinContinuing RifaximinTotal
Female9432126
Male15838196
08

Study locations

35 sites
  • Birmingham, Alabama, United States
  • Aurora, California, United States
  • Fresno, California, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Merced, California, United States
  • Sacramento, California, United States
  • San Francisco, California, United States
  • Golden, Colorado, United States
  • Washington, District of Columbia, United States
  • Macon, Georgia, United States
  • Iowa City, Iowa, United States
  • Monroe, Louisiana, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Kansas City, Missouri, United States
  • Lebanon, New Hampshire, United States
  • Bayside, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Odessa, Texas, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Madison, Wisconsin, United States
  • Calgary, Alberta, Canada
  • Victoria, British Columbia, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
09

References and documents

Publications

  • Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1390-7.e2. doi: 10.1016/j.cgh.2013.12.021. Epub 2013 Dec 21. PubMed 24365449 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2007 to primary completion in Dec 2010, 45 months.

Results were first posted in Aug 2019, 8 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
StartActual
Mar 7, 2007
Primary completionActual
Dec 8, 2010
CompletionActual
Dec 8, 2010
Results first posted
Aug 14, 2019
Last update
Aug 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686920
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Mar 7, 2007
Primary completion
Dec 8, 2010
Completion
Dec 8, 2010
Results posted
Aug 14, 2019
Last update
Aug 14, 2019

Study contacts

Lindsey Mathew
study director · Bausch Health Companies

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion